Get started
Author

Irena Bibby

Observed name: I Bibby
ORCID: 0009-0007-3105-9864
Observed ORCID: 0009-0007-3105-9864
OpenAlex ID: A5092265039
Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2023 · Christopher J.M. Williams, Faye Elliott, et al. · Clinical Cancer Research · 23
PDF
Patient and public involvement and engagement in research: who, why, when and how to get it right
2026 · Katherine Jacques, Robert J Mulligan, et al. · Frontline Gastroenterology · 1
Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves’ disease
2024 · Faye Wolstenhulme, Irena Bibby, et al. · BMJ Open · 1
PDF
Open-IBD: protocol for a longitudinal multi-omics inception cohort in inflammatory bowel disease
2026 · Robert J Mulligan, Cristina Cotobal Martin, et al. · BMJ Open Gastroenterology
PDF
P1045 The impact of patient and public involvement and engagement (PPIE) on the design and operationalisation of a multi-centre inception cohort study: Insights from Open-IBD
2026 · K Jacques, R Mulligan, et al. · Journal of Crohn s and Colitis
Supplementary Methods S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Figure S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025 · Christopher J.M. Williams, Faye Elliott, et al.
PDF
Supplementary Table S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025 · Christopher J.M. Williams, Faye Elliott, et al.
PDF
Supplementary Figure S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Table S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025 · Christopher J.M. Williams, Faye Elliott, et al.
PDF
Supplementary Table S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025 · Christopher J.M. Williams, Faye Elliott, et al.
PDF
Supplementary Figure S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025 · Christopher J.M. Williams, Faye Elliott, et al.
PDF
Better understanding of the causes, how best to treat and how to develop new medications for Crohn’s and colitis by studying human cells and gut microbes
2025 · Carol Shields, Chris Lamb, et al. · http://isrctn.com/
Supplementary Figure S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Table S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Figure S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Table S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Table S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Methods S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Figure S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Table S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Figure S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Figure S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Table S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Supplementary Table S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024 · Christopher J.M. Williams, Faye Elliott, et al.
Works count: 50
Citation count: 25
H-index: 1
I10-index: 1
Year
Topic
Type